Vincristine sulfate

Catalog No.S1241 Batch:S124109

Print

Technical Data

Formula

C46H58N4O14S
Molecular Weight 923.04 CAS No. 2068-78-2
Solubility (25°C)* In vitro DMSO 100 mg/mL (108.33 mM)
Water 50 mg/mL (54.16 mM)
Ethanol Insoluble
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Vincristine sulfate is an inhibitor of polymerization of microtubules by binding to tubulin with IC50 of 32 μM in a cell-free assay. Vincristine sulfate induces apoptosis.
Targets
Microtubules [1]
(Cell-free assay)
32 μM
In vitro Vincristine inhibits net addition of tubulin dimers at assembly ends of steady-state microtubules with Ki of 85 nM. [1] At low concentrations, Vincristine stabilizes the spindle apparatus resulting in failure of the chromosomes to segregate leading to metaphase arrest and inhibition of mitosis. At higher concentrations, Vincristine may disrupt and induce total depolymerization of microtubules. [2] Vincristine induces apoptosis in tumor cells and inhibits SH-SY5Y cell proliferation with IC50 of 0.1 μM. Vincristine induces mitotic arrest and promots the expression of caspase-3 and -9 and cyclin B, while decreasing the expression of cyclin D. [4] Vincristine induced neurotoxicity is caused by interference with microtubule function, which results in blockage of axonal transport and thus in axonal degeneration. [5]
In vivo Vincristine (3 mg/kg) administrated by a single i.p. injection to mice bearing bilateral subcutaneous xenografts Rh12 or Rh18, induces mean growth delay of >120 and >52 day, and repopulating fractions of 0.06% and 5%, respectively. [6] Vincristine acts on subcutaneous colon 38 tumors in mice by host cell-mediated vascular effects as well as by direct tubulin-mediated cytotoxicity. Vincristine (5 mg/kg) reduces tumor blood flow of tumors by nearly 75% . [7]

Protocol (from reference)

Cell Assay:[1]
  • Cell lines

    B16 melanoma cell

  • Concentrations

    10 nM

  • Incubation Time

    3 days

  • Method

    Cells are plated in 2 mL of medium in 35-mm plates at a concentration of about 5 × 104 cells/mL and grow for 24 h at 37 ℃ in an atmosphere of 5% CO2 and 95% air. Then medium is replaced with fresh medium lacking or containing 4 nM drug and proliferation is continued for 3 days. Cell counts are done each day in a Coulter Counter after detaching the cells with trypsin and EDTA.
Animal Study:[6]
  • Animal Models

    Human rhabdomyosarcoma xenografts Rh12

  • Dosages

    3 mg/kg

  • Administration

    A single i.p. administration

Customer Product Validation

Data from [Int J Mol Sci, 2012, 13, 10736-10749 ]

Data from [Data independently produced by , , Cancer Research, 2013, 73(20): 6310-22 ]

Data from [Data independently produced by , , Cell Death & Disease, 2017, doi:10.1038/cddis.2017.454]

Data from [Data independently produced by , , Chemosphere, 2018, 210:467-475]

Selleck's Vincristine sulfate has been cited by 114 publications

EFNB1 levels determine distinct drug response patterns guiding precision therapy for B-cell neoplasms [ iScience, 2024, 27(1):108667] PubMed: 38155773
Fusion-negative rhabdomyosarcoma 3D organoids to predict effective drug combinations: A proof-of-concept on cell death inducers [ Cell Rep Med, 2023, 4(12):101339] PubMed: 38118405
Identifying new biomarkers of aggressive Group 3 and SHH medulloblastoma using 3D hydrogel models, single cell RNA sequencing and 3D OrbiSIMS imaging [ Acta Neuropathol Commun, 2023, 11(1):6] PubMed: 36631900
Mitotic Dysregulation at Tumor Initiation Creates a Therapeutic Vulnerability to Combination Anti-Mitotic and Pro-Apoptotic Agents for MYCN-Driven Neuroblastoma [ Int J Mol Sci, 2023, 10.3390/ijms242115571] PubMed: 37958555
Drug Resistance in Medulloblastoma Is Driven by YB-1, ABCB1 and a Seven-Gene Drug Signature [ Cancers (Basel), 2023, 15(4)1086] PubMed: 36831428
In ovo chorioallantoic membrane assay as a xenograft model for pediatric rhabdomyosarcoma [ Oncol Rep, 2023, 49(4)76] PubMed: 36866753
RECOVER identifies synergistic drug combinations in vitro through sequential model optimization [ Cell Rep Methods, 2023, 3(10):100599] PubMed: 37797618
Elucidating minimal residual disease of paediatric B-cell acute lymphoblastic leukaemia by single-cell analysis [ Nat Cell Biol, 2022, 10.1038/s41556-021-00814-7] PubMed: 35145224
Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies [ Blood, 2022, blood.2021014304] PubMed: 35704690
Functional, structural and molecular characterizations of leukemogenic driver MEF2D-HNRNPUL1 fusion [ Blood, 2022, blood.2022016241] PubMed: 35544603

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.